Fosamprenavir Expanded Access

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00240552
First received: October 14, 2005
Last updated: October 15, 2008
Last verified: October 2008

October 14, 2005
October 15, 2008
July 2003
Not Provided
Not Provided
Incidence and frequency of serious adverse events
Complete list of historical versions of study NCT00240552 on ClinicalTrials.gov Archive Site
Not Provided
Incidence and frequency of adverse events with at least possible causality leading to permanent fosamprenavir discontinuation.
Not Provided
Not Provided
 
Fosamprenavir Expanded Access
An Open-Label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options

This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.

Not Provided
Expanded Access
Not Provided
Not Provided
HIV Infection
  • Drug: fosamprenavir
  • Drug: Telzir®
    Other Names:
    • fosamprenavir
    • Telzir®
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • HIV-1 infected subjects.
  • Subjects must belong to one of the following populations:

    1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
    2. Subjects who already receive amprenavir (Agenerase®)
    3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00240552
APV40005, SZ01V02
Not Provided
Study Director, GSK
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
GlaxoSmithKline
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP